Dougherty & Co Downgrades Myriad Genetics (MYGN) to Neutral; 2013 Reimbursement Uncertainty

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA
6. AVGO
7. SPCX
8. DE
9. OSIS
10. REAX

June 18, 2012 11:28 AM EDT
Get Alerts MYGN Hot Sheet
Price: $3.20 -0.62%

Rating Summary:
    7 Buy, 19 Hold, 4 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Dougherty & Co downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral with a price target of $22.00 (from $28.00).

Analyst, Junaid Husain, said, "...We see 2013 reimbursement uncertainty for the company’s largest revenue generator, BRACAnalysis (~81% total sales). Our anxiousness on reimbursement was heighted following last week’s release of an OIG report on coverage and payment information related to molecular diagnostic tests, including BRACAnalysis..."

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $23.68 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades